Mild Cognitive Impairment Clinical Trial
— MFYM - POfficial title:
Home Exercise, Vitamin D and Dalcroze Eurhythmics for Seniors With Mild Cognitive Impairment (MCI) or Mild Dementia
Verified date | November 2016 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Interventional |
Move for your mind is a single blind, 3-arm randomized controlled clinical pilot trial. The
study aims to test the effect of a weekly Dalcroze eurhythmics program (arm 1) and a home
strength exercise program (arm 2) against control (no exercise) on the rate of falling,
quality of life, gait performance and cognitive function. All groups receive vitamin D. In
addition the study shall test the feasibility of the recruitment and the interventions in
this target population.
The study includes 60 seniors, age 65 and older, with mild cognitive impairment or mild
dementia. Participants are recruited by the memory clinic of City Hospital Waid.
During the 12 months follow-up, participants will have 3 clinical visits (baseline, 6 and 12
month). Despite major efforts the target population is very difficult to recruit and
adherence to treatment is low. We therefore decided to stop recruitment and to use this
trial as a pilot trial for future clinical trials of the same topic.
Status | Completed |
Enrollment | 19 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Age 65+ years - Diagnosed with MCI or mild dementia by the memory clinic of City Hospital Waid Exclusion Criteria: |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Switzerland | Centre on Aging and Mobility, University of Zurich, Waid City Hospital | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich | Waid City Hospital, Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | progression of MCI/mild dementia | any progression of the cognitive disorder to a more severe state ( will be confirmed based on medical records of the memory clinic of Waid City Hospital. Evaluation of this endpoint will be supported by information from the MoCA and the TAP subtests at baseline, 6, and 12 months clinical visits. | 6 &12 months | No |
Other | Musculoskeletal pain | assessed using McGill pain map. Number of painful joints will be assessed using a joint map. | baseline, 6 and 12 month | No |
Primary | Rate of falls (any falls, low trauma falls, injurious falls) during 12 month follow-up | A fall is defined as unintentional coming to rest on the ground, floor, or other lower level (coming to rest against furniture or a wall is not considered a fall). All reported incident falls will be ascertained every 2 month (phone calls at 2, 4, 8 and 10 months and clinical visits at 6 and 12 months after baseline) with a questionnaire evaluating the circumstances of each fall and injuries associated with it. Participants will also receive a diary to record any new health event including a fall. The diary will serve as a supplementary tool to falls evaluation minimizing potential recall bias. | at month 2, 4, 6, 8, 10 and 12 after baseline | No |
Secondary | Number of participants who fell at least once during 12 months of follow up | at month 2, 4, 6, 8, 10 and 12 after baseline | No | |
Secondary | Gait variability (stride time, stride length and gait speed) | assessed by a GAITRite analysis system | Baseline, 6 & 12 months | No |
Secondary | Cognitive function | assessed using the Montreal Cognitive Assessment (MoCA) | Baseline, 6 & 12 months | No |
Secondary | Alertness | Alertness will be assessed using the two subtests "alertness" and "split alertness" of the test of attentional performance (TAP) | Baseline, 6 & 12 months | No |
Secondary | Quality of life | evaluated using the SF-36 questionnaire | Baseline, 6 and 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |